A new low molecular weight heparinoid Org 10172 as anticoagulant in hemodialysis.
A low molecular weight heparinoid (Org 10172) was compared with unfractionated heparin in 36 patients on chronic hemodialysis in an open randomized cross-over study with three anti-coagulant treatment regimens for a single hemodialysis session. The anti-coagulant regimens were: a) standard heparin (3250-4750 I.U. heparin at start of hemodialysis followed by continuous infusion of 2000-2700 I.U. per hour); b) Org 10172 administered as a single intravenous bolus of 2400 anti-Xa units at start of dialysis; c) Org 10172 administered as a single bolus of 3200 anti-Xa units at start of dialysis. Plasma anti-Xa activity during hemodialysis was highest in regimen; d) and significantly lower when heparin was used. Mean beta-thromboglobulin concentrations changed to the same extent in the three groups. Plasma platelet factor 4 concentrations were higher after the use of heparin. The extracorporeal circuit was maintained patent in all groups; the volume of blood retained in the dialyzers did not differ markedly. Org 10172 proved safe and its anticoagulant effect was sufficient at the dose levels studied.
Von Bonsdorff
M
M
Fourth Department of Medicine, Helsinki University Central Hospital, Finland.
Stiekema
J
J
Harjanne
A
A
Alapiessa
U
U
D000925:Anticoagulants / Q000008:administration & dosage*; D001760:Bleeding Time; D001772:Blood Cell Count / Q000187:drug effects; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D005260:Female; D006025:Glycosaminoglycans / Q000008:administration & dosage*; D006493:Heparin / Q000008:administration & dosage; D006497:Heparan Sulfate; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010314:Partial Thromboplastin Time; D006435:Renal Dialysis
D000925:Anticoagulants; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D006025:Glycosaminoglycans; D006493:Heparin; D006497:Heparan Sulfate; C035838:danaparoid